Propylisopropyltryptamine (PiPT), also known as N-propyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family. It reportedly produces hallucinogenic effects that resemble those of other related dialkyl tryptamine derivatives, although PiPT is reportedly relatively weak and short-lasting. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.
Use and effects According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), PiPT had not yet been evaluated.
Interactions
Chemistry PiPT is short for N-propyl-N-isopropyltryptamine. PiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines
Analogues Analogues of PiPT include methylisopropyltryptamine (MiPT), ethylisopropyltryptamine (EiPT), diisopropyltryptamine (DiPT), and dipropyltryptamine (DPT), among others.
Society and culture Legal status Canada PiPT is not a controlled substance in Canada as of 2025.
United States PiPT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
See also Substituted tryptamine
References
External links PIPT - Isomer Design The Small and Waning PIPT thread - Bluelight